|
Volumn 48, Issue 1233, 2006, Pages 34-35
|
Rituximab (Rituxan) for rheumatoid arthritis
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABATACEPT;
ADALIMUMAB;
CORTICOSTEROID;
CYCLOPHOSPHAMIDE;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
INFLIXIMAB;
METHOTREXATE;
METHYLPREDNISOLONE;
RITUXIMAB;
ANTIRHEUMATIC AGENT;
MONOCLONAL ANTIBODY;
ANGIONEUROTIC EDEMA;
BACTERIAL ARTHRITIS;
BRONCHOSPASM;
CARDIOTOXICITY;
CHILL;
CLINICAL TRIAL;
DEATH;
DRUG COST;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG SAFETY;
FEVER;
HEADACHE;
HUMAN;
HYPOTENSION;
MULTIPLE CYCLE TREATMENT;
PNEUMONIA;
RHEUMATOID ARTHRITIS;
SHORT SURVEY;
SIDE EFFECT;
SYMPTOMATOLOGY;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
URTICARIA;
VIRUS INFECTION;
VIRUS REACTIVATION;
CONTROLLED CLINICAL TRIAL;
ECONOMICS;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DRUG COSTS;
HUMANS;
METHOTREXATE;
RANDOMIZED CONTROLLED TRIALS;
|
EID: 33646845619
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (11)
|
References (7)
|